Journal: bioRxiv

Article Title: Lac-Phe mediates the anti-obesity effect of metformin

doi: 10.1101/2023.11.02.565321

Figure Lengend Snippet: (A) 300 mg/kg metformin treatment increases Lac-Phe levels in WT (n = 6), but not in CNDP2-KO (n = 7) mice. (B) Chronic metformin treatment (300 mg/kg daily) suppresses food intake of WT, but not CNDP2-KO mice. (C) Chronic metformin treatment (300 mg/kg daily) suppresses body weight of WT, but not CNDP2-KO mice. (D) 300 mg/kg metformin treatment increases circulating GDF15 levels in WT and CNDP2-KO mice. (E-F) 4 nmol subcutaneous GDF15 injection reduces food intake (E) and body weight (F) in WT and CNDP2-KO mice. Values adjusted by effects with vehicle treatment. (G) 300 mg/kg metformin treatment increases circulating GLP-1 levels in WT and CNDP2-KO mice. (H-I) 10 nmol subcutaneous Semaglutide injection reduces food intake (H) and body weight (I) in WT and CNDP2-KO mice. Values adjusted by effects with vehicle treatment. For (B) and (C), N = 6 for KO-saline, N = 7 for other groups. N = 4 – 5 in (D) and (G). N = 5 – 6 in (E), (F), (H), and (I). P values in (A) were calculated using multiple paired t tests with Holm-Šídák corrections; Welch t tests were used in (D-I).

Article Snippet: Recombinant GDF15 (957-GD) was purchased from R&D systems.

Techniques: Injection, Saline